COMP <GO>
PFE vs JNJ // REVENUE GROWTH (YOY)
Pfizer Inc. (NYSE) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: PFE 5
— JNJ 9
▲ REVENUE GROWTH (YOY) LEADER: JNJ
LAST: $30.52 (+1.90%) • MKT CAP: $170.71B
revenue-growth
-1.60%
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
revenue-growth
6.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PFE VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | PFE | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 74.30% | 67.90% | +6.40 | PFE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 5.10% | 25.50% | -20.40 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | 19.7x | 18.5x | +1.20 | JNJ | /valuation <GO> |
| Free Cash Flow Yield | 5.32% | 2.97% | +2.35 | PFE | /fcf-yield <GO> |
| Operating Margin | 15.10% | 34.70% | -19.60 | JNJ | /operating-margins <GO> |
| Net Profit Margin | 12.40% | 28.50% | -16.10 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | -1.60% | 6.00% | -7.60 | JNJ | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.10 | 5.59 | -3.49 | JNJ | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 8/9 | -1.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.10% | 7.20% | -0.10 | PFE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 66.5 | 60.4 | +6.19 | PFE | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.05 | 1.08 | -0.03 | JNJ | /macro-sensitivity <GO> |
| Forward P/E Multiple | 20.5x | 23.0x | -2.50 | PFE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $170.71B | $662.49B | -$491.79B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | PFE REV | JNJ REV | PFE GROSS % | JNJ GROSS % | PFE FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $62.58B | $94.19B | 74.3% | 67.9% | $9.07B | $19.70B |
| FY 2024 | $63.63B | $88.82B | 71.9% | 69.1% | $9.84B | $19.84B |
| FY 2023 | $50.91B | $85.16B | 44.0% | 44.0% | $6.41B | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PFE // BETA 1.05
JNJ // BETA 1.08